---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-23-000046"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:31:02.663137+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Travere Q3 net income $150.7M from bile acid sale; FILSPARI sales $8M, 430 new starts

## Summary
- Net income $150.7M ($1.97/share) includes gain from bile acid portfolio sale; prior year loss $69.7M.
- FILSPARI net sales $8.0M in Q3, 430 new patient start forms (990 total since Feb 2023 launch).
- R&D expense $60.6M, SG&A $67.8M; cash, equivalents & marketable securities $634.6M.
- Regulatory: on track for sNDA for FILSPARI in IgAN (full approval) & FSGS in Q4; EU CHMP opinion year-end.
- Completed sale of bile acid products to Mirum for up to $445M; pegtibatinase pivotal study to start by year-end.

## SEC filing metadata
- accession: 0001438533-23-000046
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000046/0001438533-23-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000046/tvtx-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-23-000046
- JSON: https://secwatch.observer/filing/0001438533-23-000046.json
- Plain text: https://secwatch.observer/filing/0001438533-23-000046.txt

## Key facts
- Earnings Releases
  Travere Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 7, 2023, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000046/0001438533-23-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.